Pravastatin Therapy and the Risk of Stroke

Background Several epidemiologic studies have concluded that there is no relation between total cholesterol levels and the risk of stroke. In some studies that classified strokes according to cause, there was an association between increasing cholesterol levels and the risk of ischemic stroke and a possible association between low cholesterol levels and the risk of hemorrhagic stroke. Recent reviews of trials of 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors have suggested that these agents may reduce the risk of stroke. Methods In a double-blind trial (the Long-Term Intervention with Pravastatin in Ischaemic Disease study), we compared the effects of pravastatin on mortality due to coronary heart disease (the primary end point) with the effects of placebo among 9014 patients with a history of myocardial infarction or unstable angina and a total cholesterol level of 155 to 271 mg per deciliter (4.0 to 7.0 mmol per liter). Our goal in the present study was to assess effects on stroke from any c...

[1]  Elisa T. Lee,et al.  Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.

[2]  Z. Li,et al.  Blood pressure, cholesterol, and stroke in eastern Asia , 1998, The Lancet.

[3]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[4]  J. Norris,et al.  Outcome in patients with asymptomatic neck bruits. , 1986, The New England journal of medicine.

[5]  D. Cox Regression Models and Life-Tables , 1972 .

[6]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[7]  A. Tonkin,et al.  Proximal aortic atheroma. An independent risk factor for cerebral ischemia. , 1995, Stroke.

[8]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[9]  R. Virmani,et al.  Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. , 1996, Journal of vascular surgery.

[10]  A. Sharrett,et al.  Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[11]  H. White,et al.  Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy , 1998 .

[12]  W. Mack,et al.  Beneficial Effects of Colestipol‐Niacin Therapy on the Common Carotid Artery. Two‐ and Four‐Year Reduction of Intima‐Media Thickness Measured by Ultrasound , 1993, Circulation.

[13]  B. Davis,et al.  Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. , 1999, Circulation.

[14]  J. Holmes,et al.  Lifetime cost of stroke in the United States. , 1996, Stroke.

[15]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[16]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[17]  P. Libby,et al.  Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. , 1998, Journal of the American College of Cardiology.

[18]  R. D'Agostino,et al.  Precursors of extracranial carotid atherosclerosis in the Framingham Study , 1994, Neurology.

[19]  J. Kjekshus,et al.  Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). , 1998, The American journal of cardiology.

[20]  S. Azen,et al.  Reduction in Carotid Arterial Wall Thickness Using Lovastatin and Dietary Therapy , 1996, Annals of Internal Medicine.

[21]  A. Yeung,et al.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. , 1995, The New England journal of medicine.

[22]  G. Gallus,et al.  Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.

[23]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[24]  J. Slattery,et al.  Prognosis and prognostic factors of retinal infarction: a prospective cohort study. , 1991, BMJ.

[25]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[26]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[27]  W. Liboni,et al.  Effect of Lipid-Lowering Treatment on Progression of Atherosclerotic Lesions—a Duplex Ultrasonographic Investigation , 1995, Angiology.

[28]  J. Crouse,et al.  Assessment and management of carotid disease. , 1992, Annual review of medicine.

[29]  C. Hennekens,et al.  An overview of trials of cholesterol lowering and risk of stroke. , 1995, Archives of internal medicine.

[30]  D. Kromhout Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts , 1995, The Lancet.

[31]  P A Wolf,et al.  American Heart Association Prevention Conference IV: prevention and rehabilitation of stroke: executive summary. , 1997, Circulation.

[32]  G. Guyatt,et al.  Effect of HMGcoA Reductase Inhibitors on Stroke , 1998, Annals of Internal Medicine.

[33]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[34]  D. Jacobs,et al.  Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. , 1989, The New England journal of medicine.

[35]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[36]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[37]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[38]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.